Integrated Care News by CFHA
MAY 19, 2025
Rather, it is an evidence-based, collaborative process that mirrors the well-established framework of using physical symptom monitoring (e.g., vital signs, bloodwork laboratory findings, and other physical test data) as a means of guiding care over time. MBC is much more than simply administering behavioral health measures.
Family Physicians of St. Joseph
SEPTEMBER 25, 2018
In 2007, Dr. Mancini joined the practice, followed by Dr. Meadows in 2012, and Dr. Gendernalik in 2015. they provide free sports physicals for youth in Berrien Springs and New Buffalo. Larger companies now dominate the healthcare landscape, yet through innovation and a dedication to exceptional patient care, Family Physicians of St.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Physician's Weekly
JUNE 19, 2025
Gowin and his colleagues analyzed data from 1,003 adults between 22 and 36 years of age who had functional magnetic resonance imaging (fMRI), urine toxicology, and cannabis use results collected at one academic site between 2012 and 2015 as part of the Human Connectome Project. The cohort (mean age, 28.7
PEMBlog
OCTOBER 16, 2023
During that initial visit, her physical exam was notable for generalized abdominal tenderness. Physical exam The patient had stable vital signs and an exam notable for tenderness to palpation over the right lower quadrant and suprapubic region without any peritoneal signs. 2012 Jan;5(1):67-70. J Hum Reprod Sci.
FDA Law Blog
AUGUST 10, 2023
Section 704(a)(4) was added to the FDCA by the Food and Drug Administration Safety and Innovation Action (FDASIA) in July 2012. Despite FDA having the authority to conduct paper inspections since the statutory provision was added to the FDCA by FDASIA in 2012, FDA did not issue a warning letter citing Section 704(a)(4) until January 2021.
FDA Law Blog
AUGUST 18, 2024
In 2012, the FDCA was modified to allow the submission of a De Novo request without the need for a prior 510(k), and set a target review time by FDA of 120 days. This amendment allowed sponsors with low or moderate risk devices to proactively employ the De Novo process. These legislative changes helped.
FDA Law Blog
FEBRUARY 29, 2024
A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. FDA-2022-E-3124 ).
Expert insights. Personalized for you.
100 
Let's personalize your content